BRPI0517253A - compostos e composições como moduladores de trajetória de ouriço - Google Patents

compostos e composições como moduladores de trajetória de ouriço

Info

Publication number
BRPI0517253A
BRPI0517253A BRPI0517253-5A BRPI0517253A BRPI0517253A BR PI0517253 A BRPI0517253 A BR PI0517253A BR PI0517253 A BRPI0517253 A BR PI0517253A BR PI0517253 A BRPI0517253 A BR PI0517253A
Authority
BR
Brazil
Prior art keywords
hedgehog
compositions
compounds
modulators
trajectory
Prior art date
Application number
BRPI0517253-5A
Other languages
English (en)
Inventor
Xu Wu
Sheng Ding
Peter G Schultz
Original Assignee
Irm Llc
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc, Scripps Research Inst filed Critical Irm Llc
Publication of BRPI0517253A publication Critical patent/BRPI0517253A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

COMPOSTOS E COMPOSIçõES COMO MODULADORES DE TRAJETóRIA DE OURIçO. A presente invenção refere-se a um método para a modulação da atividade de trajetória de sinalização de ouriço. Em particular, a invenção provê um método para a inibição de estados de crescimento aberrante que resultam de fenótipos tais como perda de função de Ptc, ganho de função de ouriço, ganho de função suavizada ou ganho de função de Gli, compreendendo o contato de uma célula com uma quantidade suficiente de um composto da fórmula I.
BRPI0517253-5A 2004-10-28 2005-10-28 compostos e composições como moduladores de trajetória de ouriço BRPI0517253A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62344404P 2004-10-28 2004-10-28
PCT/US2005/039442 WO2006050351A2 (en) 2004-10-28 2005-10-28 Compounds and compositions as hedgehog pathway modulators

Publications (1)

Publication Number Publication Date
BRPI0517253A true BRPI0517253A (pt) 2008-10-07

Family

ID=36319759

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517253-5A BRPI0517253A (pt) 2004-10-28 2005-10-28 compostos e composições como moduladores de trajetória de ouriço

Country Status (11)

Country Link
US (1) US20090209573A1 (pt)
EP (1) EP1804803A4 (pt)
JP (1) JP2008518954A (pt)
KR (1) KR20070083836A (pt)
CN (1) CN101083996A (pt)
AU (1) AU2005302279A1 (pt)
BR (1) BRPI0517253A (pt)
CA (1) CA2583812A1 (pt)
MX (1) MX2007005125A (pt)
RU (1) RU2007119637A (pt)
WO (1) WO2006050351A2 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005205201B2 (en) * 2004-01-12 2011-05-12 Merck Serono Sa Thiazole derivatives and use thereof
ITVA20060041A1 (it) * 2006-07-05 2008-01-06 Dialectica Srl Uso di composti derivati amminotiazolici, di loro composizioni farmaceutiche, nel trattamento di malattie caratterizzate dalla anormale repressione della trascrizione genica, particolarmente il morbo di huntington
PE20080948A1 (es) * 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
AU2008241527B2 (en) 2007-04-18 2014-02-13 Merck Sharp & Dohme Llc Triazole derivatives which are Smo antagonists
US8389736B2 (en) * 2007-10-16 2013-03-05 The Regents Of The University Of California Compounds having activity in correcting mutant-CFTR processing and uses thereof
CA2710858A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CN102170873B (zh) 2008-10-01 2014-07-30 诺华股份有限公司 用于治疗与hedgehog通路有关的病症的smoothened拮抗
AU2010279325B2 (en) 2009-08-05 2016-10-20 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
KR101774035B1 (ko) 2009-10-30 2017-09-01 얀센 파마슈티카 엔.브이. 이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도
CA2785204C (en) 2010-01-07 2016-01-05 Selexagen Therapeutics, Inc. Hedgehog inhibitors
WO2011085261A1 (en) * 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Hedgehog inhibitors
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
WO2013000924A1 (en) 2011-06-27 2013-01-03 Janssen Pharmaceutica Nv 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
MX2014002542A (es) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2014001314A1 (en) 2012-06-26 2014-01-03 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
AU2013289284B2 (en) 2012-07-09 2017-03-30 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
EP2925363A4 (en) 2012-11-29 2016-11-09 Strasspharma Llc METHOD FOR MODULATING FOLLICLE-STIMULATING HORMONACTIVITY
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
CA2914284A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PT3052485T (pt) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PL3302428T3 (pl) 2015-06-04 2026-04-13 Sol-Gel Technologies Ltd. Preparaty do zastosowania miejscowego do dostarczania związków inhibitora hedgehog i ich zastosowanie
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017139497A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Hedgehog inhibitor for use in relief of and treatment of pruritus or itching
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
WO2019062657A1 (zh) * 2017-09-30 2019-04-04 北京越之康泰生物医药科技有限公司 氮杂环类衍生物、其制备方法及其医药用途
WO2022019920A1 (en) 2020-07-24 2022-01-27 Verastem, Inc. Treatment of cancers using pi3 kinase isoform modulators

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
EP1028964A1 (en) * 1997-11-11 2000-08-23 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9919778D0 (en) * 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
JP2003525291A (ja) * 2000-03-01 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ２，４−二置換チアゾリル誘導体
CN100355751C (zh) * 2000-03-29 2007-12-19 西克拉塞尔有限公司 2－取代的4－杂芳基－嘧啶、其组合物及其用途
CN1173975C (zh) * 2000-04-27 2004-11-03 山之内制药株式会社 咪唑并吡啶衍生物
US6403588B1 (en) * 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
AU2001295992A1 (en) * 2000-10-24 2002-05-06 Sankyo Company Limited Imidazopyridine derivatives
CN100500663C (zh) * 2001-09-28 2009-06-17 西克拉塞尔有限公司 作为抗增殖化合物的n-(4-(4-甲基噻唑-5-基)嘧啶-2-基)-n-苯胺
EP1496905B1 (en) * 2002-04-22 2008-08-13 Johns Hopkins University School of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
JP2003313126A (ja) * 2002-04-23 2003-11-06 Sankyo Co Ltd イミダゾピリジン誘導体を有効成分とする医薬
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
KR100530988B1 (ko) * 2003-03-14 2005-11-28 한국과학기술원 봉입체 결합 단백질을 코딩하는 유전자를 결핍시키거나 증폭시켜 목적 단백질을 제조하는 방법
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
AU2005205201B2 (en) * 2004-01-12 2011-05-12 Merck Serono Sa Thiazole derivatives and use thereof
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds

Also Published As

Publication number Publication date
KR20070083836A (ko) 2007-08-24
JP2008518954A (ja) 2008-06-05
EP1804803A4 (en) 2008-07-30
CN101083996A (zh) 2007-12-05
RU2007119637A (ru) 2008-12-10
MX2007005125A (es) 2007-07-04
EP1804803A2 (en) 2007-07-11
US20090209573A1 (en) 2009-08-20
WO2006050351A2 (en) 2006-05-11
WO2006050351A3 (en) 2007-02-22
AU2005302279A1 (en) 2006-05-11
CA2583812A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
BRPI0517253A (pt) compostos e composições como moduladores de trajetória de ouriço
BRPI0711333B8 (pt) moduladores da via hedgehog
BRPI0917936A2 (pt) Moduladores de via hedgehog
BR112013000868A2 (pt) derivados de pirazol [1,5a] e tieno [3,2b] pirimidina como modulares de irak4
UA97258C2 (ru) Гербицидная композиция, применение ее для контроля сорняков в сельскохозяйственных культурах и способ контроля сорняков
WO2009027820A3 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
WO2008014291A3 (en) Compounds and compositions as hedgehog signaling pathway modulators
NO20092569L (no) Inhibitorer av Akt-aktivitet
UY32313A (es) Composiciones herbicidas que contienen compuestos de benzoilpirazol y otro compuesto herbicida
MX2009013469A (es) Insecticidas de isoxazolina.
WO2008080015A3 (en) Compounds and methods for kinase modulation, and indications therefor
PH12012502061A1 (en) Active compound combinations
MA32906B1 (fr) Derives d'isoxazole utilisables comme fongicides
BR112012007237A2 (pt) composição e método para controlar pragas artrópodes
UA90209C2 (ru) Фунгицидная композиция, способ борьбы с заболеваниями полезных растений и способ защиты товаров
WO2007109330A3 (en) S1p receptor modulating compounds
JO2872B1 (en) New vehicles
ATE487380T1 (de) Verwendung einer verbindung mit monogalactosyldiacylglycerol-synthase- hemmungsaktivität als herbizid oder algizid, herbizid- und algizidzusammensetzungen
BRPI0915589B8 (pt) combinação herbicida sinérgica de clomazone e petoxamida
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
EA200901610A1 (ru) Производные бифенилкарбоксамида в качестве модуляторов пути хеджхок
WO2009133374A3 (en) Antisapstain compositions comprising a haloalkynyl compound, an azole and an unsaturated acid
EA200700286A1 (ru) Применение замещённых производных 2-пирролидона в качестве фунгицидов и инсектицидов
WO2008030795A3 (en) Compositions and methods for inhibition of tyrosine kinases
WO2010132097A3 (en) Compositions and methods for pest control

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.